Details

Autor(en) / Beteiligte

• Wokołorczyk, Dominika
• Kluźniak, Wojciech
• Stempa, Klaudia
• Rusak, Bogna
• Huzarski, Tomasz
• Gronwald, Jacek
• Gliniewicz, Katarzyna
• Kashyap, Aniruddh
• Morawska, Sylwia
• Dębniak, Tadeusz
• Jakubowska, Anna
• Szwiec, Marek
• Domagała, Paweł
• Lubiński, Jan
• Narod, Steven A
• Akbari, Mohammad R
• Cybulski, Cezary

Titel

PALB2 mutations and prostate cancer risk and survival

Ist Teil von

• British journal of cancer, 2021-08, Vol.125 (4), p.569-575

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The objective of this study was to establish the contribution of PALB2 mutations to prostate cancer risk and to estimate survival among PALB2 carriers. We genotyped 5472 unselected men with prostate cancer and 8016 controls for two Polish founder variants of PALB2 (c.509_510delGA and c.172_175delTTGT). In patients with prostate cancer, the survival of carriers of a PALB2 mutation was compared to that of non-carriers. A PALB2 mutation was found in 0.29% of cases and 0.21% of controls (odds ratio (OR) = 1.38; 95% confidence interval (CI) 0.70-2.73; p = 0.45). PALB2 mutation carriers were more commonly diagnosed with aggressive cancers of high (8-10) Gleason score than non-carriers (64.3 vs 18.1%, p < 0.0001). The OR for high-grade prostate cancer was 8.05 (95% CI 3.57-18.15, p < 0.0001). After a median follow-up of 102 months, the age-adjusted hazard ratio for all-cause mortality associated with a PALB2 mutation was 2.52 (95% CI 1.40-4.54; p = 0.0023). The actuarial 5-year survival was 42% for PALB2 carriers and was 72% for non-carriers (p = 0.006). In Poland, PALB2 mutations predispose to an aggressive and lethal form of prostate cancer.